公开(公告)号：US20190336496A1

公开(公告)日：2019-11-07

申请号：US16277091

申请日：2019-02-15

Applicant: AbbVie Inc.

Inventor： Tamar Uziel ,  Joel D. Leverson ,  William N. Pappano ,  Dipica B. Maganbhai Haribhai ,  Rebecca Mathew ,  Fred Kohlhapp ,  Cherie K. Donawho

IPC: A61K31/496 ,  A61K31/5377 ,  C07K16/28 ,  A61P35/00

Abstract: This invention pertains to a method for the treatment of cancer in a subject comprising administering to the subject an effective amount of a selective BCL-2 inhibitor or a prodrug or pharmaceutically acceptable salt thereof in combination with an effective amount of an anti-PD-1 antibody or an anti-PD-L1 antibody.

公开(公告)号：US20150211075A1

公开(公告)日：2015-07-30

申请号：US14679889

申请日：2015-04-06

Applicant: AbbVie Inc.

Inventor： Dimitri Semizarov ,  Tamar Uziel ,  David Ching Siang Huang ,  Mark F. van Delft ,  Christin Tse ,  Richard R. Lesniewski

IPC: C12Q1/68 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57496 ,  G01N2333/4703

Abstract: The invention is directed to methods and kits that allow for identifying, classifying, and monitoring cancer patients for Bcl-2 family inhibitor therapies. The methods and compositions of the invention are directed to determining amplification of Bcl-xL and in cancer or tumor cells, or elevated Bcl-xL polypeptide expression.

Abstract translation: 本发明涉及允许鉴定，分类和监测癌症患者Bcl-2家族抑制剂疗法的方法和试剂盒。 本发明的方法和组合物涉及确定Bcl-xL和癌症或肿瘤细胞中的扩增或升高的Bcl-xL多肽表达。